SNY
Sanofi
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Sanofi has 23 disclosed suppliers and 9 disclosed customers in SEC filings.
—
Sanofi
44.35
pre 44.71 +0.84%
SentenceWe expect our sources of potential funding for the next several years to be derived primarily from sales of our commercialized products, with contributions from our existing collaborations, including royalties on sales of Leqvio by Novartis and on sales of Qfitlia by Sanofi, and any new strategic collaborations that we may enter in the future.
SentenceAficamten is an investigational, next-in-class selective small molecule cardiac myosin inhibitor discovered and developed globally by Cytokinetics. Sanofi has acquired CORXEL's rights relating to aficamten in China, Hong Kong, Macao and Taiwan for an undisclosed amount. Cytokinetics remains eligible to receive up to $ 150 million in development and commercial milestone payments from Sanofi as well as royalties in the low-to-high teens on future sales of aficamten in China, Hong Kong, Macao and Taiwan.
SentenceIn May 2024, we entered into a collaboration and license agreement with Sanofi, pursuant to which we granted Sanofi an exclusive license under certain intellectual property rights to commercialize losmapimod, an oral small molecule that we were developing for the treatment of FSHD outside of the United States and received an upfront payment of $80.0 million.
SentenceOn January 2016, the Company entered into a research collaboration and licensing agreement with Sanofi to apply its proprietary technology to the development of multi-specific antibody formats engaging NK cells to kill tumor cells through the activating receptor NKp46.
SentenceC o-exclusive licensing agreement with Novavax. The terms of the agreement include (i) a co-exclusive license to co- commercialize Novavax's current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan, and South Korea, where Novavax has existing partnership agreements); (ii) a sole license to Novavax's adjuvanted COVID-19 vaccine for use in combination with Sanofi's flu vaccines; and (iii) a non- exclusive license to use the Matrix-M adjuvant in vaccine products. Novavax received an upfront payment of $ 500 million and could receive up to $ 700 million contingent on attainment of development, regulatory and commercialization milestones, representing up to $1.2 billion in total.
SentenceIn addition, under the collaboration agreement with Regeneron on monoclonal antibodies (see Note C.1.), Sanofi is entitled to receive an additional share of quarterly profits (capped at 10 % of Regeneron's share of quarterly profits until March 31, 2022, and thereafter at 20 % ), until Regeneron has paid 50 % of the cumulative development costs incurred by the parties to the alliance.
SentenceTeva Pharmaceuticals (2023): collaboration agreement to co-develop and co-commercialize TEV'574 (duvakitug), for which positive Phase 2b clinical study results in patients with ulcerative colitis and Crohn's disease were announced on December 17, 2024;
SentenceExclusive licensing agreement with CORXEL Pharmaceuticals (CORXEL) to develop and commercialize aficamten in China, Hong Kong, Macao and Taiwan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). Aficamten is an investigational, next-in-class selective small molecule cardiac myosin inhibitor discovered and developed globally by Cytokinetics. Sanofi has acquired CORXEL's rights relating to aficamten in China, Hong Kong, Macao and Taiwan for an undisclosed amount.
SNY 20-Faccession 0001628280-26-008403
SentenceExclusive licensing agreement with RadioMedix, Inc. and Orano Med for AlphaMedix (SAR447873), a late-stage project currently being evaluated for the treatment of adult patients with unresectable or metastatic progressive somatostatin- receptor expressing neuroendocrine tumors (NETs), a rare cancer. Under the licensing agreement, Sanofi will be responsible for the global commercialization of AlphaMedix, while Orano Med will be responsible for the manufacturing of AlphaMedix through its global industrial platform currently under development. Under the terms of the agreement, RadioMedix and Orano Med received an upfront payment of € 100 million and could receive up to € 220 million based on sales milestones, as well as being eligible for tiered sales-based royalties.
SNY 20-Faccession 0001628280-26-008403
SentenceExclusive licensing agreement with RadioMedix, Inc. and Orano Med for AlphaMedix (SAR447873), a late-stage project currently being evaluated for the treatment of adult patients with unresectable or metastatic progressive somatostatin- receptor expressing neuroendocrine tumors (NETs), a rare cancer. Under the licensing agreement, Sanofi will be responsible for the global commercialization of AlphaMedix, while Orano Med will be responsible for the manufacturing of AlphaMedix through its global industrial platform currently under development. Under the terms of the agreement, RadioMedix and Orano Med received an upfront payment of € 100 million and could receive up to € 220 million based on sales milestones, as well as being eligible for tiered sales-based royalties.
SNY 20-Faccession 0001628280-26-008403
SentenceGiven the significant and growing contribution of AMVUTTRA to our total product revenues following regulatory approvals of AMVUTTRA for the treatment of ATTR-CM, our cost of goods sold, operating income and operating margin in 2025 were significantly impacted by the royalties we pay to Sanofi on global sales of AMVUTTRA under our TTR license agreements, and we expect this will continue in future years.
Sentence
o In April 2023, we announced a collaboration with Sanofi who will sponsor and manage a Phase 1/2 trial of SARCLISA ® (isatuximab-irfc), an anti-cancer antibody, and dexamethasone in combination with evorpacept for the treatment of patients with relapsed or refractory multiple myeloma.
SentenceIn December 2019, we entered into a license agreement, which has been subsequently amended (as amended, the "Sanofi License Agreement"), with Sanofi, pursuant to which we have been granted an exclusive, worldwide, sublicensable, royalty-bearing license to develop and commercialize products using the licensed compounds and know-how for CFTR modulator therapies.
Linked news
News
Expected move
No implied move.